ストックスクリーナーアプリを入手
90.42
0.87%
0.78
アフターアワーズ：
90.42
前日終値:
$89.64
開ける：
$90.01
24時間の取引高:
555.18K
Relative Volume:
1.27
時価総額：
$6.03B
収益：
-
当期純損益:
$-224.29M
株価収益率:
-23.18
EPS:
-3.9
ネットキャッシュフロー:
$-185.06M
1週間 パフォーマンス:
+2.75%
1か月 パフォーマンス:
+15.43%
6か月 パフォーマンス:
+29.23%
1年 パフォーマンス:
-13.73%
1日の値動き範囲:
$89.13
$92.89
1週間の範囲:
$84.62
$92.89
52週間の値動き範囲:
$55.53
$105.13
Nuvalent Inc Stock (NUVL) Company Profile
NUVL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
90.42 | 6.10B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-03-14 | アップグレード | UBS | Neutral → Buy |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-08-29 | 開始されました | Barclays | Overweight |
| 2024-04-17 | 開始されました | Jefferies | Buy |
| 2024-04-01 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 再開されました | Guggenheim | Buy |
| 2024-02-23 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-27 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-24 | 開始されました | Guggenheim | Buy |
| 2023-01-18 | 開始されました | Wedbush | Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
すべてを表示
Nuvalent Inc (NUVL) 最新ニュース
Custom strategy builders for tracking Nuvalent Inc.Portfolio Value Report & Risk Controlled Daily Trade Plans - newser.com
Regression analysis insights on Nuvalent Inc. performanceWeekly Loss Report & Risk Managed Investment Strategies - newser.com
Intraday pattern recognizer results for Nuvalent Inc.Earnings Growth Summary & Growth-Oriented Investment Plans - newser.com
Stifel initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com South Africa
Stifel initiates coverage on Nuvalent stock with Buy rating - Investing.com
Cantor Fitzgerald initiates Nuvalent stock with Overweight rating By Investing.com - Investing.com Australia
Can trapped investors hope for a rebound in Nuvalent Inc.Portfolio Risk Summary & Fast Entry Momentum Alerts - newser.com
Forecasting Nuvalent Inc. price range with options dataWeekly Stock Summary & Capital Efficient Trading Techniques - newser.com
Will Nuvalent Inc. stock rally after Fed decisionsJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Cantor Fitzgerald initiates Nuvalent stock with Overweight rating - Investing.com India
Multi asset correlation models including Nuvalent Inc.Market Performance Report & Expert Approved Momentum Trade Ideas - newser.com
Statistical indicators supporting Nuvalent Inc.’s strengthJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
Nuvalent to present new data on HER2 inhibitor at cancer conference - Investing.com Nigeria
Nuvalent to present new data on HER2 inhibitor at cancer conference By Investing.com - Investing.com South Africa
Preclinical intracranial activity: Nuvalent’s NVL-330 to be presented at AACR‑NCI‑EORTC Oct 24 - Stock Titan
How Nuvalent Inc. stock reacts to oil pricesBond Market & Entry Point Confirmation Signals - newser.com
What moving averages say about Nuvalent Inc.Trade Exit Summary & Weekly High Potential Stock Alerts - newser.com
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 32% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Nuvalent To Participate In The UBS 2025 Virtual Oncology Day - Barchart.com
Is Nuvalent Inc. stock bottoming outVolume Spike & Weekly Chart Analysis and Trade Guides - newser.com
Nuvalent (NASDAQ:NUVL) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Nuvalent Inc. stock trendline breakdown2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Is Nuvalent Inc. showing signs of accumulationJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
What MACD signals say about Nuvalent Inc.Trade Entry Report & Risk Managed Investment Strategies - newser.com
Is Nuvalent Inc. stock a buy before product launchesMarket Trend Review & Precise Buy Zone Tips - newser.com
The Escalator: Eli Lilly, Nuvalent, Lumen Bioscience and more - Medical Marketing and Media
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year - Investing.com
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating - 富途牛牛
Nuvalent, Inc. (NUVL) Stock Analysis: Promising Biotech With 38% Upside Potential - DirectorsTalk Interviews
What to expect from Nuvalent Inc. in the next 30 daysJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Will Nuvalent Inc. stock outperform Dow Jones index2025 Key Lessons & AI Driven Price Predictions - newser.com
Nuvalent Inc (NUVL) 財務データ
収益
当期純利益
現金流量
EPS
Nuvalent Inc (NUVL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Balcom Alexandra | Chief Financial Officer |
Oct 14 '25 |
Option Exercise |
18.93 |
20,000 |
378,600 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Oct 13 '25 |
Option Exercise |
14.79 |
20,000 |
295,825 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Oct 13 '25 |
Sale |
88.51 |
20,000 |
1,770,288 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Oct 14 '25 |
Sale |
86.20 |
20,000 |
1,724,016 |
61,734 |
| Pelish Henry E. | Chief Scientific Officer |
Oct 13 '25 |
Option Exercise |
36.39 |
7,637 |
277,903 |
73,600 |
| Pelish Henry E. | Chief Scientific Officer |
Oct 14 '25 |
Option Exercise |
25.67 |
2,433 |
62,460 |
68,396 |
| Pelish Henry E. | Chief Scientific Officer |
Oct 13 '25 |
Sale |
89.81 |
7,637 |
685,879 |
65,963 |
| Pelish Henry E. | Chief Scientific Officer |
Oct 14 '25 |
Sale |
85.78 |
2,433 |
208,699 |
65,963 |
2.96%
0.09%
大文字化:
|
ボリューム (24 時間):